This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here.
One of the big presentations of this year’s ESMO (at least in our view) comes tomorrow morning bright and early. David Spigel of Sarah Cannon Research Institute in Nashville will unveil results from the GALAXIES Lung-201 study of an anti-TIGIT therapy from iTeos Therapeutics and GSK in non-small cell lung cancer.
It’s a big moment for both iTeos and the broader efforts to develop TIGIT-targeting treatments. (To get up to speed, check out my colleague Adam Feuerstein’s preview of the presentation here.) While TIGIT was once hyped as the next great immunotherapy target, a number of failed trials has cooled that sentiment, and some drugmakers have pared their TIGIT programs.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
